TELA Bio Appoints William Plovanic to Board of Directors, Enhancing Capital Markets Expertise and Operational Leadership

TELA Bio has appointed William Plovanic to its Board of Directors, bringing capital markets expertise and operational leadership in medical technology. Plovanic currently serves as Managing Director, Healthcare Equity Research at Canaccord Genuity and has held C-level operating and board roles at Obalon Therapeutics. He will help strengthen TELA Bio's strategy and drive long-term shareholder value.